SecBot SecBot
PRESS-RELEASE ·Filed Mar 25, 2026

REGN

Regeneron Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should await the actual earnings release and call on April 29 for material updates. No action warranted based on this notice alone.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$753.70
T+0 close · Mar 25, 2026 · via day close
Latest settled
−18.73%
T+60 · $612.50
Vs SPY
−34.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $753.70entry
  2. T+1 · 8mo ago −2.10%α −0.42% · $737.85
  3. T+5 · 8mo ago +1.09%α −0.54% · $761.95
  4. T+20 · 7mo ago −0.31%α −10.98% · $751.35
  5. T+60 · 5mo ago −18.73%α −34.13% · $612.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron Pharmaceuticals announced it will release its first quarter 2026 financial results on April 29, 2026, followed by a conference call. The press release contains no financial data, guidance, or material operational updates, it is purely a scheduling notice.

Key Facts

  • Regeneron will report Q1 2026 earnings on April 29, 2026, before market open.
  • Conference call scheduled for 8:30 AM ET on the same day.
  • No financial results, guidance, or operational updates were disclosed in this release.
  • This is a routine earnings announcement notice, not a results release.

Financial Impact

None disclosed, no financial data released

Risk Factors

  • Earnings could miss consensus expectations given recent insider selling, though minimal in size.
  • Potential for volatility post-earnings if guidance is lowered or results disappoint.

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
75% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262579

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026